Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Pharmacodynamic Biomarkers to Support Biosimilar Development: Clinical Study 2: PCSK9 Inhibitors - Alirocumab and Evolocumab

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04189484
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:49.250635+00:00
Published At
2024-04-22T00:00:00+00:00
Record Updated At
2024-04-22
Results Posted At
2024-04-22
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Healthy Subjects", "Pharmacokinetics", "Pharmacodynamics"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-04-22"
protocolSection.identificationModule.nctId
"NCT04189484"
protocolSection.identificationModule.officialTitle
"Pharmacodynamic Biomarkers to Support Biosimilar Development: Clinical Study 2: PCSK9 Inhibitors - Alirocumab and Evolocumab"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2024-04-22"

Study condition terms

  • Healthy Subjects (protocolSection.conditionsModule.conditions)
  • Pharmacokinetics (protocolSection.conditionsModule.conditions)
  • Pharmacodynamics (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.